WO2001064247A3 - Method of treating cancer with anti-neurotrophin agents - Google Patents

Method of treating cancer with anti-neurotrophin agents Download PDF

Info

Publication number
WO2001064247A3
WO2001064247A3 PCT/US2001/006266 US0106266W WO0164247A3 WO 2001064247 A3 WO2001064247 A3 WO 2001064247A3 US 0106266 W US0106266 W US 0106266W WO 0164247 A3 WO0164247 A3 WO 0164247A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurotrophin
binds
treating cancer
agent
agents
Prior art date
Application number
PCT/US2001/006266
Other languages
French (fr)
Other versions
WO2001064247A2 (en
Inventor
Karen J Buchkovich
Craig A Dionne
Sheila J Miknyoczki
Bruce A Ruggeri
Original Assignee
Cephalon Inc
Karen J Buchkovich
Craig A Dionne
Sheila J Miknyoczki
Bruce A Ruggeri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc, Karen J Buchkovich, Craig A Dionne, Sheila J Miknyoczki, Bruce A Ruggeri filed Critical Cephalon Inc
Priority to EP01914537A priority Critical patent/EP1261372B1/en
Priority to NZ521165A priority patent/NZ521165A/en
Priority to AU3991301A priority patent/AU3991301A/en
Priority to MXPA02008465A priority patent/MXPA02008465A/en
Priority to CA2401604A priority patent/CA2401604C/en
Priority to JP2001563144A priority patent/JP2003525253A/en
Priority to DE60128208T priority patent/DE60128208T2/en
Priority to AU2001239913A priority patent/AU2001239913B2/en
Publication of WO2001064247A2 publication Critical patent/WO2001064247A2/en
Publication of WO2001064247A3 publication Critical patent/WO2001064247A3/en
Priority to HK03102054.6A priority patent/HK1049961B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A method of treating or preventing cancer by administering to a mammal a therapeutically effective amount of at least one anti-neurotrophin agent is described. The anti-neurotrophin agent is preferably an anti-neurotrophin antibody, an antisense molecule directed to a neurotrophin, a small organic molecule which binds a neurotrophin, or a dominant-negative mutation of a trk receptor that binds a neurotrophin. This method is particularly preferred for the treatment of prostate or pancreatic cancer. The anti-neurotrophic agents neutralize NGF, BDNF, NT-3, NT-4/5, NT-6 or NT-7 and include humanized antibodies as well as fragments thereof.
PCT/US2001/006266 2000-02-29 2001-02-28 Method of treating cancer with anti-neurotrophin agents WO2001064247A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP01914537A EP1261372B1 (en) 2000-02-29 2001-02-28 Method of treating cancer with anti-neurotrophin agents
NZ521165A NZ521165A (en) 2000-02-29 2001-02-28 Method of treating cancer with anti-neurotrophin agents
AU3991301A AU3991301A (en) 2000-02-29 2001-02-28 Method of treating cancer with anti-neurotrophin agents
MXPA02008465A MXPA02008465A (en) 2000-02-29 2001-02-28 Method of treating cancer with anti neurotrophin agents.
CA2401604A CA2401604C (en) 2000-02-29 2001-02-28 Method of treating cancer with anti-neurotrophin agents
JP2001563144A JP2003525253A (en) 2000-02-29 2001-02-28 Method of treating cancer using anti-neurotrophin agent
DE60128208T DE60128208T2 (en) 2000-02-29 2001-02-28 Method for treating cancer with anti-neurotrophin agents
AU2001239913A AU2001239913B2 (en) 2000-02-29 2001-02-28 Method of treating cancer with anti-neurotrophin agents
HK03102054.6A HK1049961B (en) 2000-02-29 2003-03-20 Method of treating cancer with anti-neurotrophin agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18594300P 2000-02-29 2000-02-29
US60/185,943 2000-02-29
US09/793,850 2001-02-27
US09/793,850 US6548062B2 (en) 2000-02-29 2001-02-27 Method of treating cancer with anti-neurotrophin agents

Publications (2)

Publication Number Publication Date
WO2001064247A2 WO2001064247A2 (en) 2001-09-07
WO2001064247A3 true WO2001064247A3 (en) 2002-02-14

Family

ID=26881613

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/006266 WO2001064247A2 (en) 2000-02-29 2001-02-28 Method of treating cancer with anti-neurotrophin agents

Country Status (13)

Country Link
US (1) US6548062B2 (en)
EP (1) EP1261372B1 (en)
JP (1) JP2003525253A (en)
CN (1) CN1227033C (en)
AT (1) ATE361100T1 (en)
AU (2) AU2001239913B2 (en)
CA (1) CA2401604C (en)
DE (1) DE60128208T2 (en)
ES (1) ES2286110T3 (en)
HK (1) HK1049961B (en)
MX (1) MXPA02008465A (en)
NZ (1) NZ521165A (en)
WO (1) WO2001064247A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100081197A1 (en) * 1997-08-14 2010-04-01 Sylvie Roux In vivo modulation of neuronal transport
JP3773733B2 (en) * 2000-01-13 2006-05-10 松下電器産業株式会社 Cathode ray tube
FR2807660A1 (en) * 2000-04-13 2001-10-19 Warner Lambert Co Use of a nerve growth factor antagonist for the manufacture of a medicament for the prevention or treatment of chronic visceral pain
CN1684708A (en) * 2001-05-30 2005-10-19 基因技术股份有限公司 Anti-NGF antibodies for the treatment of various disorders
US20060147450A1 (en) * 2002-10-04 2006-07-06 Shelton David L Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
UA80447C2 (en) * 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
PL211654B1 (en) * 2002-10-08 2012-06-29 Rinat Neuroscience Corp Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
FR2846426B1 (en) * 2002-10-28 2004-12-10 Bio Merieux METHOD FOR ASSAYING NGF FOR IN VITRO DIAGNOSIS OF BREAST CANCER AND USE IN THERAPY
NZ540730A (en) 2002-12-24 2010-09-30 Rinat Neuroscience Corp Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
PL379983A1 (en) 2003-02-19 2006-11-27 Rinat Neuroscience Corp. Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
US20050043215A1 (en) * 2003-02-19 2005-02-24 Tamara Minko Complex drug delivery composition and method for treating cancer
MEP31508A (en) * 2003-07-15 2010-10-10 Amgen Inc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
US7999071B2 (en) * 2003-12-12 2011-08-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human cytotoxic T-lymphoctye epitope and its agonist eptiope from the non-variable number of tandem repeat sequence of MUC-1
ITRM20030601A1 (en) * 2003-12-24 2005-06-25 Lay Line Genomics Spa METHOD FOR THE HUMANIZATION OF HUMANIZED ANTIBODIES AND ANTIBODIES WITH IT OBTAINED.
ES2338344T3 (en) * 2004-04-07 2010-05-06 Rinat Neuroscience Corporation PROCESS OF BONE CANCER TREATMENT THROUGH THE ADMINISTRATION OF AN ANTAGONIST OF THE NEURONAL GROWTH FACTOR.
ME00226B (en) 2004-07-15 2011-02-10 Medarex Llc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
US20090196850A1 (en) 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
JP5096167B2 (en) 2005-01-24 2012-12-12 メドイミューン リミテッド Specific binding member for NGF
ITRM20050290A1 (en) * 2005-06-07 2006-12-08 Lay Line Genomics Spa USE OF MOLECULES ABLE TO INHIBIT THE BOND BETWEEN NGF AND ITS TRKA RECEPTOR AS AN EXTENDED EFFECT ANALGESICS.
FR2896881B1 (en) * 2006-01-31 2008-04-18 Biomerieux Sa METHOD FOR DETERMINING PRONGF FOR IN VITRO DIAGNOSIS OF BREAST CANCER AND USE OF PRONGF IN THERAPY
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
MY153781A (en) * 2007-08-10 2015-03-13 Regeneron Pharma High affinity human antibodies to human nerve growth factor
CA2724830A1 (en) * 2008-05-21 2009-11-26 Centre Leon Berard Inhibition of the nt-3:trkc bound and its application to the treatment of cancer such as neuroblastoma
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
JP2012515158A (en) 2009-01-12 2012-07-05 武田薬品工業株式会社 Cancer preventive / therapeutic agent
AU2010207597A1 (en) 2009-01-24 2011-08-18 Phytopharm Plc Treatment of neurotrophic factor mediated disorders
NZ596839A (en) 2009-05-04 2014-01-31 Abbott Res Bv Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
CN102892430A (en) 2010-03-17 2013-01-23 雅培研究有限公司 Anti-nerve growth factor (ngf) antibody compositions
EP2606067B1 (en) 2010-08-19 2018-02-21 Zoetis Belgium S.A. Anti-ngf antibodies and their use
JP6105838B2 (en) * 2010-08-24 2017-03-29 国立大学法人 岡山大学 Pain treatment
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
NZ611076A (en) 2010-12-01 2015-09-25 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US8926978B2 (en) 2011-10-25 2015-01-06 Anaptysbio, Inc. Antibodies directed against nerve growth factor (NGF)
CA2875783C (en) 2012-06-06 2018-12-11 Zoetis Llc Caninized anti-ngf antibodies and methods thereof
MX362394B (en) 2012-06-08 2019-01-15 Glenmark Pharmaceuticals Sa Humanized anti-trka antibodies with amino acid substitutions.
TWI703158B (en) * 2015-09-18 2020-09-01 美商希佛隆公司 Antibodies that specifically bind to tl1a
CA3093772C (en) 2018-03-12 2024-04-16 Zoetis Services Llc Anti-ngf antibodies and methods thereof
WO2023111157A1 (en) 2021-12-16 2023-06-22 Intervet International B.V. Caninized and felinized antibodies to human ngf
US20230348608A1 (en) 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Treatment Of Arthropathy Based Upon Stratification Of Osteoarthritis Polygenic Risk Score

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993009798A1 (en) * 1991-11-12 1993-05-27 Regeneron Pharmaceuticals, Inc. Therapeutic and diagnostic methods based on tissue specific nt-3 expression and receptor binding
WO1994006935A1 (en) * 1992-09-11 1994-03-31 Cephalon, Inc. A method for the detection and treatment of prostate disease
US5844092A (en) * 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026363A1 (en) * 1994-03-29 1995-10-05 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Neurotrophin-6: a new member of the neurotrophin family

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993009798A1 (en) * 1991-11-12 1993-05-27 Regeneron Pharmaceuticals, Inc. Therapeutic and diagnostic methods based on tissue specific nt-3 expression and receptor binding
WO1994006935A1 (en) * 1992-09-11 1994-03-31 Cephalon, Inc. A method for the detection and treatment of prostate disease
US5844092A (en) * 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHANG H ET AL: "The neurotrophin (NT)-Trk axes are an important therapeutic target in human pancreatic cancer.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, no. 41, March 2000 (2000-03-01), 91st Annual Meeting of the American Association for Cancer Research.;San Francisco, California, USA; April 01-05, 2000, March, 2000, pages 812, XP001015650, ISSN: 0197-016X *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, WOOLF CLIFFORD J: "Phenotypic modification of primary sensory neurons: The role of nerve growth factor in the production of persistent pain.", XP002175590, Database accession no. PREV199698828031 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; February 1999 (1999-02-01), RO LONG-SUN ET AL: "Effect of NGF and anti-NGF on neuropathic pain in rats following chronic constriction injury of the sciatic nerve.", XP002175589, Database accession no. PREV199900141371 *
PAIN, vol. 79, no. 2-3, February 1999 (1999-02-01), pages 265 - 274, ISSN: 0304-3959 *
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON B BIOLOGICAL, vol. 351, no. 1338, 1996, 1996, pages 441 - 448, ISSN: 0962-8436 *

Also Published As

Publication number Publication date
ES2286110T3 (en) 2007-12-01
AU3991301A (en) 2001-09-12
MXPA02008465A (en) 2003-03-10
EP1261372A2 (en) 2002-12-04
CN1227033C (en) 2005-11-16
DE60128208T2 (en) 2008-01-10
HK1049961B (en) 2007-09-14
HK1049961A1 (en) 2003-06-06
CA2401604A1 (en) 2001-09-07
NZ521165A (en) 2004-08-27
CA2401604C (en) 2011-05-24
US6548062B2 (en) 2003-04-15
JP2003525253A (en) 2003-08-26
ATE361100T1 (en) 2007-05-15
AU2001239913B2 (en) 2005-12-08
EP1261372B1 (en) 2007-05-02
WO2001064247A2 (en) 2001-09-07
DE60128208D1 (en) 2007-06-14
US20010046959A1 (en) 2001-11-29
CN1420785A (en) 2003-05-28

Similar Documents

Publication Publication Date Title
WO2001064247A3 (en) Method of treating cancer with anti-neurotrophin agents
JP2003525253A5 (en)
WO2001000245A3 (en) HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
PT817627E (en) PROTEIN INHIBITORS CINASE C
BR0012196A (en) Method of treating a tumor in mammals using maytansinoid conjugates and anti-erbb receptor antibody and industrialized article
ES2159318T3 (en) INHIBITORS OF PROTEIN QUINASA C.
AU2458001A (en) Method for treating inflammation
AU3327701A (en) Humanized anti-ccr2 antibodies and methods of use therefor
ATE474854T1 (en) RSV NEUTRALIZING ANTIBODIES WITH VERY HIGH AFFINITY
IL139700A (en) Immunotherapeutic composition for the treatment of prostate cancer
HK1087018A1 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
WO2003041736A3 (en) Method for the treatment of cardiotoxicity induced by antitumor compounds
WO2002055530A3 (en) Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
WO2004030607A3 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
WO1998020835A3 (en) Method of treating hyperlipidemia in humans
BR9910589A (en) Humanized antibody, process to produce humanized antibody vtm1-1, pharmaceutical composition, and, process to treat a patient suffering or at risk from the toxic effects of a verotoxin, and cell line
BR9807980A (en) Use of a compound and compound to treat a mammal with cognitive impairment
WO2000035430A3 (en) Homer a new target of treating psychiatric disorders
AU1608400A (en) Method of treating arthritis with human parvovirus b19 antigens or antibodies against same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2401604

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2001 563144

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/008465

Country of ref document: MX

Ref document number: 018058108

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2001239913

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 521165

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001914537

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001914537

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 521165

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 521165

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001239913

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2001914537

Country of ref document: EP